We identified COL10A1 as a marker of high-risk BCC subtypes, particularly in sclerosing/infiltrative and basosquamous subtypes. This could serve as a prognostic biomarker and a target for personalized treatment.
This study explores a new therapeutic approach for NRAS-mutated melanomas, targeting drug-resistant cells through ROS induction and metabolic vulnerabilities.
Investigating PDE4B variants in Native American populations, this study highlights their impact on ALL relapse and the need for personalized treatment approaches.